<DOC>
	<DOCNO>NCT00002551</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know treatment regimen effective rectal cancer . PURPOSE : Randomized phase III trial compare effectiveness different regimen combination chemotherapy plus radiation therapy treat patient rectal cancer surgically remove .</brief_summary>
	<brief_title>SWOG-9304 Chemotherapy Plus Radiation Therapy Treating Patients With Rectal Cancer That Has Been Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall relapse free survival patient stage II III rectal cancer treat one follow three regimen : bolus injection fluorouracil ( 5-FU ) prior follow pelvic irradiation plus protracted venous infusion ( PVI ) 5-FU radiosensitization v PVI 5-FU prior follow pelvic irradiation plus PVI 5-FU radiosensitization v bolus 5-FU leucovorin calcium levamisole prior follow pelvic irradiation . II . Describe relapse pattern tolerance associate regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord type prior surgery ( abdominoperineal resection v anterior resection ) , nodal status ( N0 vs N1 v N2-3 ) , depth tumor invasion ( T1-2 v T3 v T4a v T4b ) , time surgery study entry ( 20-45 day v 46-70 day ) , participate center , performance status ( 0-1 v 2 ) . Patients randomize one three treatment arm . Arm I : Patients receive fluorouracil ( 5-FU ) IV day 1-5 29-33 . 5-FU give continuous infusion begin day 57 continue concurrently radiotherapy 5 week . Following 28 day break treatment patient receive 5-FU IV day 1-5 28 day course . Postradiotherapy treatment repeat total 2 course absence disease progression unacceptable toxicity . Arm II : Patients receive 5-FU IV continuously day 1-42 . 5-FU radiotherapy administer arm II . Arm III : Patients receive leucovorin calcium ( CF ) IV follow 5-FU IV day 1-5 29-33 . Patients also receive oral levamisole twice daily day 1-3 , 15-17 , 29-31 , 43-45 . CF IV 5-FU IV give day 57-60 85-88 concurrently radiotherapy . Following 28 day break treatment patient receive CF IV 5-FU IV day 1-5 29-33 oral levamisole twice daily day 1-3 , 15-17 , 29-31 , 43-45 absence disease progression unacceptable toxicity . All patient receive radiotherapy 5 day per week 5 week start day 57 . Patients follow every 4 month 2 year , every 6 month 4 year , annually death . PROJECTED ACCRUAL : A total 1,800 patient ( 600 per arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levamisole</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage II III adenocarcinoma rectum Tumor extend bowel wall perirectal fat soft tissue ( TNM T34 , N0 , M0 ) Nodes involve tumor ( TNM T14 , N13 , M0 ) Tumor completely resect en bloc gross microscopic evidence residual disease Circumferential ( radial ) margin resect adherent tumor must specifically document free disease ( sole exception extraperitoneal serosal margin ) No evidence metastasis No regional nodal metastasis ( metastasis outside pelvis ) resect en bloc primary lesion No distant peritoneal metastasis ( metastasis direct extension primary tumor ) even grossly resect ( direct extension another structure permit ) Abdominopelvic CT require unless : Bilirubin , SGOT , alkaline phosphatase within normal limit , AND Operative report describe liver normal exploration No tumor colonic origin , i.e . : Lower edge tumor peritoneal reflection portion tumor retroperitoneally locate ( usually posteriorly ) define surgeon laparotomy OR Lower margin tumor 12 cm less anal verge proctoscopic exam No prior history rectal cancer No stage II III cancer extrapelvic colon within past 5 year Complete surgical resection least 5 year prior protocol registration allow provided therapy administer Synchronous modify stage I IIa colorectal cancer ( nodal involvement penetration muscularis propria ) completely resect allow Registration 20 70 day definitive surgical procedure require Chemotherapy must begin later day 70 follow surgery Concurrent registration protocol SWOG9419 allow patient adequate tissue sample PATIENT CHARACTERISTICS : Age : Over 18 Performance status : SWOG 02 Hematopoietic : WBC least 4,000/mm3 Platelet count normal Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Not specify Other : No chronic ulcerative colitis No serious medical illness would preclude protocol therapy No psychiatric condition would preclude informed consent No noncolorectal malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Adequately treat carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Other : No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>